Financial Performance - OnKure Therapeutics reported cash and cash equivalents of approximately $96.7 million as of March 31, 2025, expected to fund operations through multiple anticipated milestones into Q4 2026[5][17]. - The net loss for Q1 2025 was $15.9 million, or $1.19 per share, compared to a net loss of $9.5 million, or $30.37 per share, in Q1 2024[8][18]. - Interest income for Q1 2025 was $1.1 million, compared to $0.3 million in Q1 2024, reflecting improved cash management[18]. - Total operating expenses for Q1 2025 were $17.0 million, significantly higher than $9.8 million in Q1 2024, indicating increased investment in R&D and G&A[18]. Research and Development - Research and development (R&D) expenses increased to $13.0 million for Q1 2025, up from $8.6 million in Q1 2024, primarily due to higher personnel-related costs and clinical trial expenses[6]. - The PIKture-01 trial has completed dose escalation in Part A, with only one patient experiencing dose limiting toxicities, and a mature clinical update is expected in the second half of 2025[4][11]. - OnKure is actively enrolling patients in Part B of the PIKture-01 trial, evaluating OKI-219 in combination with fulvestrant, with no dose limiting toxicities observed to date[11]. - The company plans to announce a pan-mutant selective development candidate in Q2 2025, targeting approximately 10-fold selectivity against common PI3Ka mutations[3][11]. - OnKure aims to solidify its leadership in developing PI3K inhibitors with the ongoing PIKture-01 trial and the advancement of its pan-mutant program[2][3]. General and Administrative Expenses - General and Administrative (G&A) expenses rose to $4.0 million in Q1 2025, compared to $1.3 million in Q1 2024, driven by increased personnel-related costs and legal expenses[7].
OnKure Therapeutics, Inc.(OKUR) - 2025 Q1 - Quarterly Results